Keyphrases
Adverse Events
14%
Body Composition Parameters
14%
C-reactive Protein
57%
Combined Antiretroviral Therapy (cART)
28%
Double-blind Trial
14%
Fat Distribution
14%
Fat Redistribution
14%
GH Secretion
14%
Growth Factors
14%
Growth Hormone Treatment
100%
High Dose
28%
HIV Patients
100%
HIV-associated Lipodystrophy Syndrome
28%
Immune Parameters
14%
Inflammation
100%
Insulin-like
14%
Life Expectancy
14%
Long-run Risk
14%
Placebo
28%
Randomized Placebo-controlled Trial
100%
Recombinant Human Growth Hormone (r-hGH)
100%
Recombinant Human Growth Hormone Therapy
71%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
28%
Thymopoiesis
14%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
8%
C Reactive Protein
33%
Endocrine Therapy
100%
Growth Hormone
100%
HIV
100%
HIV Associated Lipodystrophy
16%
Human Growth Hormone
100%
Inflammation
100%
Life Expectancy
8%
Placebo
25%
Placebo-Controlled Study
100%
Somatomedin C
8%
Urokinase Receptor
16%
Immunology and Microbiology
Blood Plasma
11%
Body Composition
11%
C-Reactive Protein
44%
Drug Megadose
22%
Growth Hormone Release
11%
Human immunodeficiency virus
100%
Immunity
11%
Life Expectancy
11%
Low Drug Dose
100%
Somatomedin C
11%
Urokinase Receptor
22%